Register
Login

Trending Topic

Ophtalmologist visit with close up eye photo healthcare and sight health optics advertising AI generative
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Since its inception in November 2022, ChatGPT-3.5 has gained increasing popularity.1,2 ChatGPT is an artificial intelligence (AI) language application that performs online tasks and mimics human conversations using a question-and-answer format.3 The interface has found widespread use in several industries, with applications ranging from programming, business, education and healthcare.4 To contextualize this new technology, it is important […]

Anat Loewenstein, EURETINA 2022: Home Monitoring for Age-related Macular Degeneration

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 15th 2022

It was a pleasure to interview Prof. Anat Loewenstein (Tel Aviv Medical Center, Tel Aviv, Israel) on her EURETINA presentation discussing the advantages of home monitoring of age-related macular degeneration, and the results of a study evaluating a new device for home monitoring.

The abstract ‘Functional and anatomical options for home monitoring in the era of long duration treatments for AMD’ was presented at EURETINA 2022, 1–4 September 2022

Questions:

  1. What are the advantages of home rather than in-office monitoring of age-related macular degeneration? (00:21)
  2. Could you tell us a little about the home monitoring device you have evaluated? (01:03)
  3. What were the design and outcome measures of your pilot study? (01:58)
  4. What were the study findings? (03:38)
  5. What questions remain unanswered about these devices, and what future studies are planned? (04:24)

Disclosure: Anat Loewenstein is a consultant for Roche, Novartis, NotalVision, Bayer and Beyeonics.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed as a highlight of EURETINA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup